Skip to Content
Fund Spy: Morningstar Medalist Edition

The Best and Worst Medalists of 2015's First Quarter

Small growth and biotech exposure led, while large value lagged.

Mentioned: , , , , , , , , ,

International-equity funds beat domestic-stock funds in 2015's first quarter through March 26; small cap edged large cap, and growth trounced value. Here's a look at some of the best and worst Morningstar Medalist funds of the year's opening frame.

Among international funds, a rising dollar tempered the returns of unhedged foreign-stock funds, but overseas equity offerings still turned in some of the best absolute performances of the year thus far. Funds with significant exposure to Japan and India, as well as smaller companies, did the best. Indeed, two Matthews funds with Morningstar Analyst Ratings of Bronze-- Matthews Japan (MJFOX) and  Matthews India (MINDX)--were up 16.6% and 8.9%, respectively. These were among the most impressive results of the year- and  quarter-to-date through March 26 in Morningstar Manager Research's coverage universe.

Dan Culloton does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.